Kymera Therapeutics, Inc. (KYMR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$117.39+0.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KYMR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 23.5% |
| Our one-year growth estimate | diamond | -51.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 74.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KYMR — officer change
Dated 2026-07-27
Chief Medical Officer (CMO) — Jared Gollob, M.D.: Dr. Gollob retired from his role as CMO and will be succeeded by Dr. Terence Rooney.
Why it matters: Data from this trial will show KT-579's safety and how well it works. Good results could help with more development.
Supportive ifData from the KT-579 Phase 1 trial shows it is safe and well-tolerated in healthy volunteers.
Worry ifData from the KT-579 Phase 1 trial shows safety concerns or lack of efficacy.
Why it matters: If revenue goes above this amount, it shows strong growth. It also backs management's focus.
Supportive ifQ2 revenue was over $34 million. This shows strong growth momentum.
Worry ifQ2 revenue reported below $34 million, suggesting growth may be slowing.
Why it matters: Starting Phase 3 trials would indicate confidence in KT-621's efficacy and safety. It could lead to a faster path to market.
Supportive ifAnnouncement of Phase 3 trials for KT-621 begins by mid-2027.
Worry ifDelay in starting Phase 3 trials beyond mid-2027.
Why it matters: A strong cash position supports ongoing clinical trials and operations, which is crucial for growth.
Supportive ifCash and cash equivalents reported above $1.5 billion in Q2 earnings.
Worry ifCash and cash equivalents reported below $1.5 billion in Q2 earnings.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$170 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $420 loss on $10,000 · 4.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,774 loss on $10,000 · 27.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The healthcare sector is maturing. If revenue growth picks up, it could benefit Kymera.
Supportive ifHealthcare sector revenue growth speeds up to 10% or more.
Worry ifHealthcare sector revenue growth slows down to less than 5%.
Why it matters: The IND filing for KT-200 could open new treatment options for patients. Progress here shows the strength of partnerships.
Supportive ifThe timeline for the KT-200 IND filing is out. They also shared updates on clinical studies.
Worry ifDelays in the KT-200 IND filing or lack of partnership updates.
Why it matters: Less operating losses mean better cost control. This shows the company is more efficient.
Supportive ifOperating losses were under -$84 million. This shows better control of costs.
Worry ifOperating losses are still more than -$84 million. This shows cost management is still a problem.
Why it matters: Maintaining a strong cash position is crucial for funding ongoing trials and operations. Any changes could impact growth plans.
Watch forKymera says cash and investments are stable or growing. This confirms funding until 2029.
Also watch forKymera says cash reserves have dropped a lot. This raises worries about funding.
Why it matters: Topline data will show if KT-621 is effective for atopic dermatitis. This could boost investor confidence.
Supportive ifThe BROADEN2 trial data shows a big improvement in EASI scores.
Worry ifThe data shows no big change in EASI scores.
Why it matters: A new COO could change strategy and operations. This may affect the company's direction.
Watch forAnnouncement of a new COO with relevant experience and a strong track record.
Also watch forNo new COO has been appointed. This may cause uncertainty in leadership.
Why it matters: This data will show if KT-621 is effective for atopic dermatitis. Positive results could boost confidence in the drug's potential.
Supportive ifData from the KT-621 BROADEN2 Phase 2b trial shows a big improvement in atopic dermatitis.
Worry ifData shows no big improvement or bad effects in patients.
Why it matters: Data from this trial will indicate if KT-579 is safe and effective. Positive results could support further development.
Supportive ifData from the KT-579 Phase 1 trial shows strong IRF5 breakdown and good safety.
Worry ifData shows no big IRF5 breakdown or safety issues.
Why it matters: Keeping a strong cash position is key for funding trials and operations.
Worry ifCash and cash equivalents stay steady or grow, helping until 2029.
Less concerning ifCash position drops a lot, raising worries about future funding.
Why it matters: An IND filing would signal progress in the partnership with Gilead and the potential for new treatments.
Supportive ifGilead announces the IND filing timeline for KT-200 is on track for 2027.
Worry ifGilead delays the IND filing for KT-200 beyond 2027.